Vir Biotech Raises $150 Million in Stock Offering

The $10.00-per-share offering funds the company's pipeline, with underwriters holding an option on 2.25 million more shares.

Updated on Nov. 13, 2026 in Biotech

Vir Biotech Raises $150 Million in Stock Offering

Vir Biotechnology priced an underwritten public offering of 15,000,000 common shares at $10.00 per share, which the company expects to yield $150 million in gross proceeds before underwriting discounts and expenses. This is a financing announcement, not a product or clinical milestone; the shares are a capital raise by a publicly traded company.

Why it matters

The raise gives Vir additional capital to fund its research pipeline in a sector where clinical-stage biotechs routinely depend on equity markets. The pricing and size offer a read on investor appetite for infectious-disease and immunology-focused drug developers at this point in the cycle.

The offering is 15,000,000 common shares priced at $10.00 each, implying $150 million in gross proceeds before underwriting discounts and offering expenses. Underwriters hold a 30-day option on up to 2,250,000 more shares at the same price, which would add $22.5 million if fully exercised; the source does not disclose net proceeds or allocation.

The players

Vir Biotechnology, Inc.

A San Francisco-based, publicly traded biotechnology company developing antibody and immunotherapy candidates for infectious diseases and other conditions.

Leerink Partners

A Boston-based investment bank that serves as a bookrunning manager for the offering and provides prospectus access.

Morgan Stanley

A New York-based global investment bank serving as a bookrunning manager for the offering.

Evercore ISI

The institutional equities arm of Evercore, based in New York, serving as a bookrunning manager for the offering.

Raymond James

A Florida-based financial services firm serving as co-manager for the offering.

The details

Vir sold the shares through a registration statement filed with the SEC on November 12, 2026, which became automatically effective upon filing, with a preliminary prospectus supplement filed the same day. All shares in the offering are being sold by the company itself, so the proceeds flow to Vir rather than to existing shareholders. Leerink Partners, Morgan Stanley and Evercore ISI are bookrunning managers, with Raymond James as co-manager, and the underwriters' option lets them buy additional shares at the offering price within 30 days.

Timeline

  1. November 12, 2026: Registration statement filed with the SEC and preliminary prospectus filed.

  2. November 13, 2026: Pricing of the public offering announced.

  3. November 16, 2026: Expected closing of the offering, subject to customary closing conditions.

The Tech Race

Equity raises like this one let clinical-stage biotechs fund the trials that decide which antibody and immunotherapy platforms reach market. The offering places Vir's capital base alongside other infectious-disease developers competing for the same investor dollars.

For most readers this is a capital-markets event with no immediate effect on available treatments. Investors buying at the offering price, and anyone tracking Vir's share count, will see the new shares settle on the expected closing date.

The takeaway

Watch whether the underwriters exercise the 2,250,000-share option before the 30-day window closes, which would signal additional demand at $10.00 per share. The closing on November 16, 2026 will confirm the final gross proceeds.

What happens next

Closing of the offering is expected on November 16, 2026, subject to customary closing conditions, and the underwriters' 30-day option period will run from pricing.

Further reading

For more on how drug developers finance their pipelines, see the Biotech section.